Compare · MOTS vs WST
MOTS vs WST
Side-by-side comparison of Motus GI Holdings Inc. (MOTS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOTS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $21.02B, about 1300.0x MOTS ($16.2M).
- WST has hit the wire 7 times in the past 4 weeks while MOTS has been quiet.
- WST has more recent analyst coverage (15 ratings vs 1 for MOTS).
- Company
- Motus GI Holdings Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.18-30.42%
- $297.59+0.78%
- Market cap
- $16.2M
- $21.02B
- 1M return
- -
- +18.69%
- 1Y return
- -
- +41.45%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 7
- Recent ratings
- 1
- 15
Motus GI Holdings Inc.
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MOTS
- Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form 15-12G filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.
Latest WST
- Sr. VP & Chief HR Officer Favorite Annette F exercised 2,817 shares at a strike of $83.47 and sold $859,753 worth of shares (2,817 units at $305.20) (SEC Form 4)
- VP, Chief Accounting Officer Winters Chad exercised 896 shares at a strike of $173.22 and sold $269,399 worth of shares (896 units at $300.67) (SEC Form 4)
- West to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.